Citation Impact
Citing Papers
The Hepatitis C Virus NS3 Protein: A Model RNA Helicase and Potential Drug Target
2007
Insertion of Green Fluorescent Protein into Nonstructural Protein 5A Allows Direct Visualization of Functional Hepatitis C Virus Replication Complexes
2004 StandoutNobel
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target.
2007
Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism
2009 StandoutNobel
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Regulation of microRNA function in animals
2018 Standout
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Treatment of HCV infection with the novel NS3/4A protease inhibitors
2014
The Nonstructural Protein 3 Protease/Helicase Requires an Intact Protease Domain to Unwind Duplex RNA Efficiently
2004
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape
2018
Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies
2016 StandoutNobel
The Functional Interaction of the Hepatitis C Virus Helicase Molecules Is Responsible for Unwinding Processivity
2004
Multi-input chemical control of protein dimerization for programming graded cellular responses
2019 StandoutNobel
euHCVdb: the European hepatitis C virus database
2006 StandoutNobel
Unravelling hepatitis C virus replication from genome to function
2005 StandoutNatureNobel
Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and NS4A
2004
Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir
2016
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Modelling hepatitis C therapy—predicting effects of treatment
2015
The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA
2015
Hepatitis C
2015
Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies
2017
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
A Brownian motor mechanism of translocation and strand separation by hepatitis C virus helicase
2005
Interferon α–Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1
2012 StandoutNobel
Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease–helicase
1999
Daclatasvir-Like Inhibitors of NS5A Block Early Biogenesis of Hepatitis C Virus–Induced Membranous Replication Factories, Independent of RNA Replication
2014
The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding
2002
Molecular Determinants of TRIF Proteolysis Mediated by the Hepatitis C Virus NS3/4A Protease
2005
Determinants for Membrane Association of the Hepatitis C Virus RNA-dependent RNA Polymerase
2001 StandoutNobel
Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus
2010
Successes and Challenges on the Road to Cure Hepatitis C
2015
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
2005 Standout
Structural biology of hepatitis C virus
2004
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
2016
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
The NS5A Protein of Hepatitis C Virus Is a Zinc Metalloprotein
2004 StandoutNobel
Hepatitis C Virus NS2/3 Processing Is Required for NS3 Stability and Viral RNA Replication
2005
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
New therapeutic strategies for hepatitis C
2002 StandoutNobel
TMEM41B Is a Pan-flavivirus Host Factor
2020 StandoutNobel
Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1–7 and Escape Variants
2017
Replication of hepatitis C virus
2007 StandoutNobel
Amphipathic Helix-Dependent Localization of NS5A Mediates Hepatitis C Virus RNA Replication
2003 StandoutNobel
Replication of hepatitis C virus
2000
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
2020 Standout
A cis -Acting Replication Element in the Sequence Encoding the NS5B RNA-Dependent RNA Polymerase Is Required for Hepatitis C Virus RNA Replication
2004 StandoutNobel
Genetic Analysis of the Carboxy-Terminal Region of the Hepatitis C Virus Core Protein
2009 StandoutNobel
Hepatitis C Virus Co-Opts Ras-GTPase-Activating Protein-Binding Protein 1 for Its Genome Replication
2011 StandoutNobel
Protease inhibitor therapy for hepatitis C virus-infection
2018
Determinants of the Hepatitis C Virus Nonstructural Protein 2 Protease Domain Required for Production of Infectious Virus
2009 StandoutNobel
Antiviral Stilbene 1,2-Diamines Prevent Initiation of Hepatitis C Virus RNA Replication at the Outset of Infection
2011 StandoutNobel
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus
2019 StandoutNobel
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications
2015
An N-Terminal Amphipathic Helix in Hepatitis C Virus (HCV) NS4B Mediates Membrane Association, Correct Localization of Replication Complex Proteins, and HCV RNA Replication
2004 StandoutNobel
The C Terminus of Hepatitis C Virus NS4A Encodes an Electrostatic Switch That Regulates NS5A Hyperphosphorylation and Viral Replication
2007 StandoutNobel
A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1
2019 StandoutNobel
Mutations in the Yellow Fever Virus Nonstructural Protein NS2A Selectively Block Production of Infectious Particles
2002 StandoutNobel
Interferon-Stimulated Genes: A Complex Web of Host Defenses
2014 StandoutNobel
Studying Hepatitis C Virus: Making the Best of a Bad Virus
2007 StandoutNobel
Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication
2002 StandoutNobel
Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein
2016
Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious Virus
2007 StandoutNobel
Identification of Residues Required for RNA Replication in Domains II and III of the Hepatitis C Virus NS5A Protein
2007 StandoutNobel
Efficient Replication of Hepatitis C Virus Genotype 1a RNAs in Cell Culture
2003 StandoutNobel
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Stimulation of Hepatitis C Virus (HCV) Nonstructural Protein 3 (NS3) Helicase Activity by the NS3 Protease Domain and by HCV RNA-Dependent RNA Polymerase
2005
A Dynamic View of Hepatitis C Virus Replication Complexes
2008 StandoutNobel
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
2019 StandoutNobel
Genetic and Functional Characterization of the N-Terminal Region of the Hepatitis C Virus NS2 Protein
2013 StandoutNobel
The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions
2018
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication
2004 StandoutNobel
Works of A Howe being referenced
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
2015
Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
2014
A novel recombinant single‐chain hepatitis C virus ns3‐ns4a protein with improved helicase activity
1999
The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis
2014
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018
2018
Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C
2014
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
2015
Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection
2014
P0891 : Resistance analysis of virologic failures in Hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: The C-worthy study
2015
Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir
2015
Development of boceprevir: a first‐in‐class direct antiviral treatment for chronic hepatitis C infection
2013
O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks
2015